| Description | The antibody ADI-15946 is a human IgG against ebola virus. It potently neutralizes EBOV and BDBV but lacks neutralizing and protective activity against SUDV. It also showed dose-dependent enhancement of neutralizing activity. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | EBOV |
| Cross Reactivity | BDBV |
| Function | The antibody is capable of neutralizing EBOV and BDBV but not SUDV. |
| Isotype | IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA, Neut |
| Application Notes | High-binding 96-well ELISA plates were coated with 50 μL GP antigens in PBS at 4 μg/mL, and allowed to bind for 1 h at room temperature. After washing, the wells were blocked with PBS containing 3% bovine serum albumin for 1 h at room temperature, followed by washing then incubation with ADI-15946 or one of its mutant derivatives in serial dilutions of PBS. A horseradishperoxidase conjugated anti-human secondary antibody was added and allowed to bind for 1 h at room temperature and then subsequently detected by ultra-TMB substrate. Optical density was measured at 450 nm, and absorbance readings were subjected to a nonlinear regression analysis to generate binding curves and calculate an EC50 value. ELISA assays were performed in triplicate, across seven 5-fold dilutions, beginning at 1000 ng/ml. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Western Blot Protocol |
| Target | EBOV |
| Alternative Name | Ebola virus |
| Research Area | Infectious Disease |
| Related Disease | Ebola virus disease |
